DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to inform that news of recent FDA Cancer Drug Approval puts Cannabis Science in a very good position moving forward with its current Cancer solutions.
Erivedge was given a fast six-month review because there are no approved treatments for advanced basal cell carcinoma. See FDA Announcement here.
“For the FDA to approve a drug with serious side effects within six months, suggests that the Cannabis Science should receive similar consideration when we submit our application for the treatment of basal cell carcinoma,” said Dr. Melamede, CEO, Cannabis Science. Click here for further information on side effects associated with Erivedge.
Cannabis Science is currently assisting numerous cancer patients suffering from a variety of cancers, who are self-medicating with cannabis extracts. Cannabis Science extracts can be legally used in humans in states allowing medical marijuana. This situation puts Cannabis Science in the unique position of knowing the effectiveness of its formulations before applying to the FDA. The success of Cannabis Science approach is dramatically demonstrated with the photo documentation available on our website www.cannabisscience.com under breaking news. Similar positive results from treating various cancer types have been observed following systemic treatments when more than a topical treatment is required.
“Whereas treatment with Erivedge is estimated to cost $7,000 per month for a total treatment plan of approximately $75,000, the Cannabis Science treatment is estimated to cost at least ten fold less,” added Dr. Melamede. “Because of the FDA focus on protecting the public from the possible harm that is so often associated with conventional pharmaceuticals, the reality of what is happening in medical marijuana states needs be incorporated into the federal approval process. Americans suffering from various forms of cancer, including skin cancer, need the FDA to place patients first when considering our up coming application.”
A comparison between Erivedge and Cannabis Science treatments is informative. According to the FDA: “The most common side effects observed in patients treated with Erivedge were muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue, distorted sense of taste, decreased appetite, constipation, vomiting, and loss of taste function in the tongue.” Cannabis-based botanicals actually can be used to treat most of these side effects.
Dr. Melamede adds, “How ironic it is that the medicine of the past will become the medicine of the future as safe and cost effective cannabis-based botanicals displace conventional pharmaceuticals for the benefit of mankind.”
You can view the above images as well as all Cannabis Science’ success on the Cannabis Science website www.cannabisscience.com, click “Breaking News” and you will find the associated news releases and images from of each patient. You can view each patient’s documentation and images by clicking: “View Images of 1st Self-Medicated Patient & The Apparent Success”, “View Images of 2nd Self-Medicated Patient & The Apparent Success”, and “View Images of 3rd Self-Medicated Patient & His Apparent Success.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
Robert Kane, 1-561-234-6929
Investor Relations Management
KEYWORDS: United States Europe North America Colorado
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Research FDA Science